AI and Pathology Giants Partner to Sharpen Cancer Trial Accuracy

HUNTSVILLE, Ala. and HAMBURG, Germany – March 24, 2026 – In a significant move to enhance the precision of cancer research, biospecimen and laboratory services leader Discovery Life Sciences has partnered with the AI-powered digital pathology firm Mindpeak. The collaboration, announced today, aims to tackle one of the most persistent hurdles in clinical trials: the subjective and often variable interpretation of cancer biomarkers by pathologists.

By integrating Mindpeak's artificial intelligence platform into Discovery’s global clinical trial laboratory services, the alliance intends to standardize the analysis of immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) slides. This technological fusion promises to reduce inconsistencies, de-risk biomarker-driven drug development, and ultimately instill greater confidence in the critical decisions that determine the fate of new cancer therapies.

The Human Bottleneck in Precision Medicine

For decades, the pathologist's microscope has been the gold standard for diagnosing cancer and assessing biomarkers—proteins and other substances that can indicate how a patient's tumor might behave or respond to treatment. However, this critical step relies on human interpretation, which can vary significantly from one expert to another. This inter-reader variability is a well-documented challenge that can lead to inconsistent patient stratification in clinical trials, potentially enrolling the wrong patients or misjudging a drug's efficacy.

The consequences are profound, contributing to costly trial failures and delaying the availability of life-saving treatments. As therapies become more targeted and biomarker profiles more complex, the need for a more objective, reproducible standard has become urgent. Inconsistent validation and a lack of clear evaluation guidelines have only compounded the issue, creating a major bottleneck in the pipeline for precision medicines.

"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences, in a statement. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies."

A Digital Co-Pilot for Pathologists

The partnership leverages Mindpeak's sophisticated AI algorithms to act as a digital co-pilot, providing a quantitative and consistent analysis of tissue images. The technology is designed not to replace pathologists, but to augment their expertise by automating the painstaking process of cell counting and scoring, thereby improving both accuracy and efficiency. Mindpeak's platform offers what it calls "0-click" solutions, which can instantly analyze IHC-stained tissue images without manual adjustments, a key feature for handling variability in sample preparation across different labs.

Validation for this approach is growing. A recent multinational study conducted by Mindpeak and AstraZeneca on HER2 scoring—a critical biomarker in breast cancer—demonstrated significant gains. The AI-assisted method correctly identified 24% more cases as HER2 ultralow, improved concordance among pathologists from 64% to 80%, and reduced the average time spent reading each case by 36%. By utilizing modern explainable AI (xAI) methods, the company also aims to make its algorithms transparent, helping to build the trust necessary for widespread adoption among clinicians.

The collaboration will also utilize Mindpeak's AI-guided microdissection algorithms, allowing researchers to isolate specific regions of tissue with pinpoint accuracy for further analysis.

"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," stated Felix Faber, Founder and CEO of Mindpeak.

Fusing AI with Global Clinical Infrastructure

While Mindpeak provides the advanced AI engine, Discovery Life Sciences brings the vast clinical and logistical infrastructure needed to deploy it at scale. Discovery is a powerhouse in the clinical trial support space, having supported more than 2,000 trial programs, with 350 currently active. The company's deep experience is further exemplified by its Biomarker Academy, a peer-to-peer training program that has educated over 6,000 pathologists in biomarker interpretation since its inception in 2008.

This partnership is part of a broader strategic push by Discovery to integrate AI across its services. The company previously announced a partnership with PathAI to bring AI-enabled insights to its massive biobank, focusing on automated quality control and tumor microenvironment characterization from H&E-stained slides. The new alliance with Mindpeak extends these capabilities into the more complex and nuanced realms of IHC and mIF analysis, which are crucial for many modern targeted therapies and immunotherapies.

By coupling Mindpeak's AI with its own established tissue biomarker services and regulatory experience—including over 35 IVDR-compliant studies in the past four years—Discovery aims to offer biopharma clients a streamlined, data-driven, and highly reproducible solution for their most demanding clinical trials.

Navigating a New Frontier of Regulation and Adoption

The integration of AI into clinical decision-making is not without its challenges. The competitive landscape is heating up, with companies like Ibex, Paige.AI, and Visiopharm also developing AI pathology solutions. More importantly, the regulatory environment is rapidly evolving to keep pace with the technology.

Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are developing frameworks to govern AI and machine learning-based medical devices. The EU's AI Act, which will be fully enforced by 2026, automatically classifies medical diagnostic tools as "high-risk," mandating stringent compliance, transparency, and assessments to prevent algorithmic bias. Navigating these regulatory pathways will be a critical task for the partnership.

Beyond regulation, widespread adoption hinges on overcoming practical barriers, including the cost of implementation, pathologist acceptance, and seamless integration into existing laboratory workflows. By pairing Mindpeak's pathologist-centric training academy with Discovery's own extensive educational programs, the partners hope to smooth the transition and demonstrate the value of an AI-augmented workflow.

Further details on the partnership, including specific use cases and data, are expected to be unveiled at the upcoming American Association for Cancer Research (AACR) Annual Meeting in April, where the alliance will host a flash talk at the Discovery Life Sciences exhibit.